EN
Clinical Characteristics and Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma: a Single-Center Experience From Southern Turkey
Abstract
Purpose: Non‑Hodgkin lymphoma (NHL) accounts for 8‑10% of all childhood cancers. In this study, we aimed to describe the epidemiological and clinical characteristics and treatment outcomes of pediatric NHL patients treated at a tertiary center.
Methods: The oncologic records of the patients diagnosed and followed up as NHL between 2013 and 2023 were reviewed retrospectively.
Results: A total of 36 patients were enrolled in this study. The most common pathologic subtype was lymphoblastic lymphoma (LL) (n=21, 58.3%) followed by Burkitt lymphoma (BL) (n=10, 27.8%), diffuse large B-cell non-Hodgkin lymphoma (DLBCL) (11.1%, n=4), and anaplastic large cell lymphoma (ALCL) (2.8%, n=1). Overall survival (OS) and event-free survival (EFS) were significantly longer in patients without bone marrow (BM) involvement (p=0.001 and p=0.02, respectively). EFS was significantly longer in patients without central nervous system (CNS) involvement (p=0.038). OS and EFS did not differ significantly according to NHL subtypes (p>0.05). There was no significant difference in OS according to age groups (p=0.7).
Conclusion: The OS with NHL has significantly improved. With the development of effective treatment regimens based on various pathologic subtypes, the result of pediatric NHL has significantly improved in recent years. The survival rates have reached >90%.
Keywords
Ethical Statement
This study was approved by the Ethical Committee for Acibadem University, with the assigned decision no: 2024-6/233 and date: 18.04.2024.
References
- 1. Kutluk T, Yeşilipek A. Pediatric Cancer Registry in Turkey 2009-2021 (TPOG & TPHD). JCO 2022;40:e22020. https://doi.org/10.1200/JCO.2022.40.16_suppl.e22020
- 2. Karalexi MA, Georgakis MK, Dessypris N, et al. Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data. Hematol Oncol. 2017 Dec;35(4):608-618. doi: 10.1002/hon.2347. 3. Huang MS, Weinstein HJ. Non-Hodgkin lymphoma. In:Fish JD, Lipton JM, Lanzkowsky P, eds. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 7th edition. Academic Press: Cambridge, MA, USA; 2021: pp. 473-83.
- 4. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022 Jul;36(7):1720-1748. doi: 10.1038/s41375-022-01620-2. Epub 2022 Jun 22. Erratum in: Leukemia. 2023 Sep;37(9):1944-1951.
- 5. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010 Jun;102(3):83-7.
- 6. Britto TI, Fattah SA, Rahman MAU, Chowdhury MAU. A Systematic Review on Childhood Non-Hodgkin Lymphoma: An Overlooked Phenomenon in the Health and Research Sector of Bangladesh. Cureus. 2023 Sep 25;15(9):e45937. doi: 10.7759/cureus.45937.
- 7. Ekström-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma--a review. Acta Oncol. 2006;45(3):258-71. doi: 10.1080/02841860500531682. PMID: 16644568.
- 8. Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA; EUROCARE Working Group. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009 Apr;45(6):992-1005. doi: 10.1016/j.ejca.2008.11.042. Epub 2009 Feb 21. PMID: 19231160.
- 9. Huang MS, Weinstein HJ. Non-Hodgkin lymphoma. In:Fish JD, Lipton JM, Lanzkowsky P, eds. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 7th edition. Academic Press: Cambridge, MA, USA; 2021: pp. 473.
Details
Primary Language
English
Subjects
Haematology , Cardiovascular Medicine and Haematology (Other)
Journal Section
Research Article
Early Pub Date
September 24, 2024
Publication Date
October 1, 2024
Submission Date
May 6, 2024
Acceptance Date
July 26, 2024
Published in Issue
Year 2024 Volume: 15 Number: 4